Blood Cancer: A curse
DOI:
https://doi.org/10.61841/tkr54790Keywords:
malignancies, blood cancer, spleen, lymphatic system, lymphoma, leukemiaAbstract
A large variety of different malignancies are caused by blood cancer. This group includes lymph node, lymph tube, tonsil, thymus, spleen and digestive lymph tissue cancer, blood and lymphatic system. The most common types of blood cancer are leukemia, myeloma, starting at the bone marrow, and lymphoma, beginning in the lymphatic system. It is not clear what causes these cancers. With the development of leukemia and myeloma inside the bone marrow, it can hinder the capacity of the bone marrow to produce normal blood cells, including white blood cells, red blood cells and platelets. This can lead to recurrent infections, anemia and quick flushing. Lymphomas, which usually appear as lymph node enlargement, can also prevent the body from fighting infections. Therefore, myelomas create an abnormal protein which causes symptoms in other parts of the body, weakens the bones. The diagnosis of blood cancer has improved significantly, leading to higher remission and survival rates. Remission takes place when no cancer symptom is present. Nearly 1 million people today in the United States experience or have recovered from cancer of the blood. Blood cancer patients may have bleeding problems. Today, cancer is a household word, with at least one close person, a relative or friend, a neighbor or colleague, being diagnosed with cancer, being closely associated with human beings.
Downloads
References
[1] A. Md Zulfekar, “Blood Cancer Therapy,” pp. 1–21, 2018.
[2] W. Wangiyana, P. Cornish, and M. Ryan, “Arbuscular mycorrhizas in various rice growing environments and their implication for low soybean yields on vertisol soil in Central Lombok, Indonesia,” IOSR J. Environ. Sci. Toxicol. Food Technol., vol. 10, no. 12, pp. 51–57, 2016.
[3] P. B. B. Sangita P. Ingole, . Aruna U. Kakde, “Review of Cancer Statistics in India,” Int. J. Adv. Signal Image Sci., vol. 1, no. 1, pp. 1–4, 2015.
[4] “(PDF) Cancer Scenario in India with Future Perspectives.” [Online]. Available: https://www.researchgate.net/publication/230560896_Cancer_Scenario_in_India_with_Future_Perspectives. [Accessed: 24-Jan-2020].
[5] “Cancer Profile of India.”
[6] Section, “Letter from the President & CEO Our Impact SECTION 3.”
[7] “National Estimation of Blood Requirement in India.”
[8] “A note about this booklet.”
[9] E. Barbarotto, T. D. Schmittgen, and G. A. Calin, “MicroRNAs and cancer: Profile, profile, profile,” International Journal of Cancer, vol. 122, no. 5. pp. 969–977, 2008.
[10] C. K. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, “Cancer Statistics Review, 1975-2015 - SEER Statistics,” SEER Cancer Stat. Rev., 2017.
[11] N. Howlander et al., “SEER Cancer Statistics Review, 1975-2016,” Natl. Cancer Inst., pp. 1–7, 2016.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
